Not all humans who shed virus at the corneal surface get severe HSK lesions suggesting an intricate mechanism involved in the development of HSK. In this report, while using the C57BL/6 mouse model, we demonstrate that not all HSV-1–infected eyes develop severe HSK lesions as determined by the extent of neovascularization and opacity of the infected cornea. The corneas with severe HSK lesions exhibit a significantly higher amount of proinflammatory neuropeptide, substance P, in comparison with the corneas with mild HSK lesions. In addition, the corneas with higher levels of SP also have higher amounts of proinflammatory cytokines (IFN-γ and IL-6) and chemokines (CCL3 and CXCL2), the molecules that are regulated by SP. The SP in the corneal stroma of eyes with severe HSK lesions could come from nerve fibers and/or immune cell types as determined by our results. Most importantly, treatment with SP antagonist, spantide I, during the clinical phase of HSK significantly reduced the severity of the corneal opacity and angiogenesis. To our knowledge this is the first study to demonstrate the relative contribution of corneal SP in regulating the severity of HSK lesions in a mouse model.
Differential rates of viral clearance from infected eyes may cause the development of mild and severe HSK lesions. However, eye swabs taken from infected eyes at different time points postinfection showed no statistically significant difference in viral load in the corneas that developed mild or severe HSK lesions. Our results are in agreement with a recent report where no significant difference in the viral load was determined in the corneal tear film of the eyes that did or did not develop HSK in a BALB/c mouse model.
27 It has also been shown that even though replicating virus in the cornea is required to induce immunoinflammatory reactions in the corneal stroma of infected eyes, the virus is not needed to sustain the inflammation that causes stromal tissue damage.
28 Therefore, the development of severe HSK lesions might depend on proinflammatory molecules that promote an ongoing inflammation.
Neuropeptides are well reported to either promote or suppress an ongoing inflammation by acting on either immune or nonimmune cell types. SP is a proinflammatory neuropeptide that belongs to a family of bioactive peptides, the tachykinins. It has been shown that elevated levels of SP in the cornea after
Pseudomonas aeruginosa infection promotes corneal inflammation and participate in the development of bacterial keratitis.
29 Even though earlier studies have shown the level of SP in the cornea after ocular HSV-1 infection,
30,31 the relative contribution of SP in regulating the severity of HSK lesions is not known. We determined that the corneas with severe HSK lesions display higher amounts of SP when compared with the corneas with mild HSK lesions. Moreover, the corneas with higher amounts of SP also exhibit higher levels of IL-6, IFN-γ, CCL3, and CXCL2 proinflammatory molecules that are known to orchestrate the corneal stromal tissue damage resulting into the development of severe HSK lesions. Because SP is known to induce the expression of IL-6, IFN-γ, CCL3, and CXCL2,
23 it is possible that SP in the inflamed cornea regulates the development of severe HSK lesions by promoting the expression of these proinflammatory molecules in the cornea.
SP exerts its action on both immune and nonimmune cell types by binding to the SP receptors NK1R, NK2R, and NK3R, with highest affinity toward NK1R.
12 We determined NK1R expression on both CD45−ve and CD45+ cell types in the inflamed cornea when measured during the clinical phase of HSK suggesting that SP might exert its action on both corneal resident and infiltrating immune cell types. Binding of SP to NK1R results in the internalization of SP-NK1R complex, thereby decreasing the level of expression of membrane-bound NK1R molecules.
32 Our studies show higher intracellular level of NK1R expression in both CD45− and CD45+ cells during the clinical phase, a time period when SP is present in abundance in the inflamed cornea. It is possible that an active interaction between SP and NK1R resulted in the internalization of NK1R and thereby increased the intracellular level of NK1R.
Studies carried out in mice models clearly demonstrate that the development of the corneal opacity, and the severe HSK lesions begin during the clinical phase of disease. One can speculate that the molecules that are differentially expressed during preclinical and clinical phases of disease may regulate the extent of the corneal opacity in HSV-1–infected eyes. Our results show a dramatic increase in the amount of SP in the cornea during the clinical phase of HSK demonstrating the possible involvement of SP in the development of severe HSK lesions. SP receptor antagonists have been used in multiple studies to demonstrate the effect of SP in chronic inflammatory conditions.
12,24 Our results determined that blocking of SP interaction with its receptor in the cornea during the clinical phase of HSK reduce the corneal opacity and angiogenesis. Antagonist injection resulted in reduced frequency of neutrophils and CD4 T cells in the cornea as well as reduced amounts of IL-6 and CCL3 proteins, thereby demonstrating an active participation of corneal SP in the regulation of cellular and molecular events involved in the development of severe HSK lesions.
HSK is a disease of the corneal stroma where resident stromal keratocytes and/or fibroblasts and infiltrating immune cell types after ocular HSV-1 infection participate in corneal tissue damage by secreting free radicals and matrix-metalloproteinases.
33 –35 Therefore, studies are carried out to determine whether SP is present in the corneal stroma of eyes with severe or mild HSK lesions. Our results clearly demonstrate that SP is largely localized in the corneal stroma of eyes with severe but not mild HSK lesions and may exert its action on cell types present in the corneal stroma. Previous studies have shown that both neuronal and nonneuronal cell types can produce SP.
8,10 The naïve cornea is largely innervated with nerve fibers that originate from the sensory neurons present in the ophthalmic branch of the trigeminal ganglia.
19 Moreover, it has been shown that nerve fibers in the naïve cornea exhibit SP.
16 In addition to neuronal source, SP is also expressed in immune cell types like macrophages and dendritic cells.
36 –38 Our data clearly show colocalization of SP with β-III tubulin and IA
b+ cells suggesting both nerve fibers as well as antigen-presenting cells as a source of SP in the corneal stroma during the clinical phase of HSK. The presence of SP-exhibiting nerve fibers in the corneal stroma of the eyes with severe HSK lesions is somewhat surprising as a recent study has shown significant but not complete loss of nerve fibers in the cornea during infectious keratitis in humans.
39,40 Because nerve fibers can get regenerated after peripheral nerve injury, it is possible that SP-expressing nerve fibers in the posterior stroma is the outcome of the regeneration of damaged nerve fibers. In fact, vascular endothelial growth factor (VEGF), an angiogenic factor that is present in abundance in the corneas with severe HSK, has been shown to participate in the regeneration of the corneal nerve fibers.
41 On the basis of the results shown in this study, we propose that SP present in the corneal stroma of the eyes with severe HSK lesions are actively involved in orchestrating stromal tissue damage by exerting its action on both stromal keratocytes and infiltrating immune cell types.
Supported by National Eye Institutes Grant EY020625.
The authors thank Shravan K. Chintala for taking the pictures of eyes with severe and mild HSK lesions.